These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 9334379)

  • 1. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection.
    Murakami T; Nakajima T; Koyanagi Y; Tachibana K; Fujii N; Tamamura H; Yoshida N; Waki M; Matsumoto A; Yoshie O; Kishimoto T; Yamamoto N; Nagasawa T
    J Exp Med; 1997 Oct; 186(8):1389-93. PubMed ID: 9334379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr(5,12),Lys7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection.
    Tamamura H; Imai M; Ishihara T; Masuda M; Funakoshi H; Oyake H; Murakami T; Arakaki R; Nakashima H; Otaka A; Ibuka T; Waki M; Matsumoto A; Yamamoto N; Fujii N
    Bioorg Med Chem; 1998 Jul; 6(7):1033-41. PubMed ID: 9730240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140.
    Tamamura H; Xu Y; Hattori T; Zhang X; Arakaki R; Kanbara K; Omagari A; Otaka A; Ibuka T; Yamamoto N; Nakashima H; Fujii N
    Biochem Biophys Res Commun; 1998 Dec; 253(3):877-82. PubMed ID: 9918823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection.
    Murakami T; Zhang TY; Koyanagi Y; Tanaka Y; Kim J; Suzuki Y; Minoguchi S; Tamamura H; Waki M; Matsumoto A; Fujii N; Shida H; Hoxie JA; Peiper SC; Yamamoto N
    J Virol; 1999 Sep; 73(9):7489-96. PubMed ID: 10438838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4.
    Xu Y; Tamamura H; Arakaki R; Nakashima H; Zhang X; Fujii N; Uchiyama T; Hattori T
    AIDS Res Hum Retroviruses; 1999 Mar; 15(5):419-27. PubMed ID: 10195751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of selective antagonists against an HIV second receptor].
    Tamamura H
    Yakugaku Zasshi; 2001 Nov; 121(11):781-92. PubMed ID: 11725546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A peptide derived from bee venom-secreted phospholipase A2 inhibits replication of T-cell tropic HIV-1 strains via interaction with the CXCR4 chemokine receptor.
    Fenard D; Lambeau G; Maurin T; Lefebvre JC; Doglio A
    Mol Pharmacol; 2001 Aug; 60(2):341-7. PubMed ID: 11455021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure.
    Arakaki R; Tamamura H; Premanathan M; Kanbara K; Ramanan S; Mochizuki K; Baba M; Fujii N; Nakashima H
    J Virol; 1999 Feb; 73(2):1719-23. PubMed ID: 9882387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissociation of the signalling and antiviral properties of SDF-1-derived small peptides.
    Heveker N; Montes M; Germeroth L; Amara A; Trautmann A; Alizon M; Schneider-Mergener J
    Curr Biol; 1998 Mar; 8(7):369-76. PubMed ID: 9545196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor.
    Doranz BJ; Grovit-Ferbas K; Sharron MP; Mao SH; Goetz MB; Daar ES; Doms RW; O'Brien WA
    J Exp Med; 1997 Oct; 186(8):1395-400. PubMed ID: 9334380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide-lead CXCR4 antagonists with high anti-HIV activity.
    Fujii N; Tamamura H
    Curr Opin Investig Drugs; 2001 Sep; 2(9):1198-202. PubMed ID: 11717804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry.
    Bleul CC; Farzan M; Choe H; Parolin C; Clark-Lewis I; Sodroski J; Springer TA
    Nature; 1996 Aug; 382(6594):829-33. PubMed ID: 8752280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paradoxical downregulation of CXC chemokine receptor 4 induced by polyphemusin II-derived antagonists.
    Masuda R; Oishi S; Tanahara N; Ohno H; Hirasawa A; Tsujimoto G; Yano Y; Matsuzaki K; Navenot JM; Peiper SC; Fujii N
    Bioconjug Chem; 2012 Jun; 23(6):1259-65. PubMed ID: 22486464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains.
    Berson JF; Long D; Doranz BJ; Rucker J; Jirik FR; Doms RW
    J Virol; 1996 Sep; 70(9):6288-95. PubMed ID: 8709256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists.
    De Clercq E; Schols D
    Antivir Chem Chemother; 2001; 12 Suppl 1():19-31. PubMed ID: 11594685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes.
    Tamamura H; Omagari A; Oishi S; Kanamoto T; Yamamoto N; Peiper SC; Nakashima H; Otaka A; Fujii N
    Bioorg Med Chem Lett; 2000 Dec; 10(23):2633-7. PubMed ID: 11128640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II).
    Masuda M; Nakashima H; Ueda T; Naba H; Ikoma R; Otaka A; Terakawa Y; Tamamura H; Ibuka T; Murakami T
    Biochem Biophys Res Commun; 1992 Dec; 189(2):845-50. PubMed ID: 1472056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Replacement of the V3 region of gp120 with SDF-1 preserves the infectivity of T-cell line-tropic human immunodeficiency virus type 1.
    Yonezawa A; Hori T; Takaori-Kondo A; Morita R; Uchiyama T
    J Virol; 2001 May; 75(9):4258-67. PubMed ID: 11287575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1.
    Oberlin E; Amara A; Bachelerie F; Bessia C; Virelizier JL; Arenzana-Seisdedos F; Schwartz O; Heard JM; Clark-Lewis I; Legler DF; Loetscher M; Baggiolini M; Moser B
    Nature; 1996 Aug; 382(6594):833-5. PubMed ID: 8752281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A study of anti-HIV compounds which interfere the virus entry via coreceptor CXCR4].
    Kanbara K; Fujii N; Nakashima H
    Kansenshogaku Zasshi; 2000 Mar; 74(3):237-44. PubMed ID: 10783578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.